Original article: Modeling Alzheimer's disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 10, 2013, Pages

  Delor, I ^a   Charoin, J E ^b   Gieschke, R ^b   Retout, S ^b   Jacqmin, P ^a  

^a Life Sciences Services   (Belgium)

^b Pharma Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; CLINICAL DEMENTIA RATING SCALE SUM OF BOXES; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE ONSET TIME; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONSET AGE; PRIORITY JOURNAL; QUESTIONNAIRE; VERY ELDERLY;

EID: 84891802127     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.54     Document Type: Article

References (22)

1. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127 (2010).
2. Weiner, M.W. et al.; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers. Dement. 6, 202-211 (2010).
3. Weiner, M.W. et al.; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers. Dement. 8, S1-68 (2012).
4. Ito, K. et al.; Alzheimer's Disease Neuroimaging Initiative. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers. Dement. 7, 151-160 (2011).
5. Samtani, M.N. et al.; Alzheimer's Disease Neuroimaging Initiative. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J. Clin. Pharmacol. 52, 629-644 (2012).
6. Samtani, M.N. et al. Disease progression model in MCI subjects from Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br. J. Clin. Pharmacol. 75, 146-161 (2013).
7. Yang, E. et al.; Alzheimer's Disease Neuroimaging Initiative. Quantifying the pathophysiological timeline of Alzheimer's disease. J. Alzheimers Dis. 26, 745-753 (2011).
8. De Meyer, G. et al.; Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956 (2010).
9. Coley, N., Andrieu, S., Jaros, M., Weiner, M., Cedarbaum, J. & Vellas, B. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers. Dement. 7, 602-610 (2011).
10. Petersen, R.C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74, 201-209 (2010).
11. Henneman, W.J. et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72, 999-1007 (2009).
12. Barnes, J. et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol. Aging 30, 1711-1723 (2009).
13. Barnes, J. et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage 53, 1244-1255 (2010).
14. Jernigan, T.L. & Gamst, A.C. Changes in volume with age-consistency and interpretation of observed effects. Neurobiol. Aging 26, 1271-1274 (2005). (Pubitemid 41338542)
15. Jack, C.R. Jr et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers. Dement. 7, 474-485 (2011).
16. Keihaninejad, S., Heckemann, R.A., Fagiolo, G., Symms, M.R., Hajnal, J.V. & Hammers, A.; Alzheimer's Disease Neuroimaging Initiative. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 50, 1427-1437 (2010).
17. Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T. & Tensfeldt, T.; Alzheimer's Disease Working Group. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers. Dement. 6, 39-53 (2010).
18. Carlsson, K.C., Savic, R.M., Hooker, A.C. & Karlsson, M.O. Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J. 11, 148-154 (2009).
19. Fjell, A.M et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Azheimer's disease. J. Neurosc. 30, 2088-2101 (2010).
20. Ye, J. et al.; Alzheimer's Disease Neuroimaging Initiative. Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol. 12, 46 (2012).
21. Beal, S.L., Sheiner, L.B., Boeckmann, A.J. & Bauer, R.J. NONMEM user's guides. (Icon Development Solutions, Ellicott City, MA, 1989-2011).
22. Hastie, T.J. & Tibshirani, R.J. Generalized additive models. In: Monographs on Statistics and Applied Probability (Chapman & Hall, London, 1990).